TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: GLUCAGON activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Degree of Disability or Dependence in the Daily Activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: complete pathological response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: implant survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Who Experience Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Barthel's Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Posttraumatic Diagnostic Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients being alive
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients having no major amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with healed ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV drug risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV sex risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference in Bacterial Colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPE carriage
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Echocardiographic Epicardial Fat Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spectrum of HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Associated clinical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Response During Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of DCA
Endpoint domain: Adverse events/effects
Primary endpoint: Net urine output at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Subjects Who Withdrew Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Completed the Mailed FIT Test Screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Production of cardiomyocytes and engineered tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Haemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects for Antibodies Against Fluviral Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects for Antibodies Against Fluviral Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnetic resonance volumetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total dose of propofol in mg/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of propofol in mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional need for opioids during surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Tryptophan metabolites in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating free fetal DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse Events (AEs) Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Remission of tumor volume ≥20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stress response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Any illicit opioid used
Endpoint domain: Adverse events/effects
Primary endpoint: re-arrest
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: FMT-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: tumor detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incremental Area Under the Plasma Glucose Concentration-time Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of modern family planning users
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Penta 1 doses administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Penta 3 doses administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cmax (Maximum concentration of drug)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-24 hr (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (Time to maximum concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in atrial fibrillation burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Technical Skill as Measured by OSATS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Surgical Site Occurrence Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Intervention Adherence: Number of Surgeon Participants who Complete All Requisite Training and Session
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative residual astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of systemic host immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative cognitive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HIV viral Load (VL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication persistence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Annualized Rate of Clinically Relevant Asthma Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of people who continue drinking raw date palm sap
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of people who stop drinking sap or who drink sap from skirt protected trees
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects achieving PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Biofilm quantity and quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptoms of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Demonstrating Proper Use of Arcoxia® and Celebrex®
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of biliary complication
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of MDR bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Delayed healing or non-union fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ADR of screening colonoscopies
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: SLE activity measurement with SELENA Systemic Lupus Erythematosus Disease Activity Index assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Severity of the Most Bothersome Symptom of Vaginal Dryness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ECG signal quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful closure of PDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Horizontal Saccadic α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Horizontal Saccadic β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vancouver Scar Scale (VSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in MDS-UPDRS Part III Off Medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Composite ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with death
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with new myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Knee Injury and Osteoarthritis Outcome Score4 (KOOS4)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Flow induced Dilation of the Brachial Artery (FMD%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gut bacterial community diversity and composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIEF-questionnaire-value
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: high sensitive C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of periodontal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in behavioral performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Body Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical status as indicated by NYHA functional classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vaginal Delivery Within 24 Hours of Labor Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bulbar Function Scale (CNS-BFS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in preschoolers Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical Activity Opportunities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Personal and Social Performance scales (PSP)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Short-version of the Udvalg for Kliniske Undersogelser (short-version UKU)
Endpoint domain: Adverse events/effects
Primary endpoint: Wisconsin Card Sorting test (WCST)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants Achieving ACR20 Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile in terms of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 100% epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postel-Merle d'Aubigné (PMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Clinically Symptomatic Respiratory Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Referral patterns for cardiac care and testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of median power frequency (MPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of amplitude (A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of surgical revisions
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of postoperative pseudoarthrosis
Endpoint domain: Adverse events/effects
Primary endpoint: evaluation postoperative pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Renal function assessed by calculated GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants Reporting Overall Flushing Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Severity Scores of Overall Flushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline on Day 21 in Relative Abundance of CAMP mRNA in Lesional and Non-Lesional Skin for Atopic Dermatitis Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline on Day 21 in Relative Abundance of CAMP mRNA in Non-Lesional Skin for Non-Atopic Dermatitis Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline on Day 21 in Relative Abundance of CAMP mRNA in Lesional and Non-Lesional Skin for Psoriatic Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Heart to mediastinum (H/M) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Washout Ratio (WR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Mean Daily-Average-Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of TCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraceptive efficacy (Pearl Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percent Change From Baseline in Final Daily Average OCS Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Placement Success
Endpoint domain: Mortality/survival
Primary endpoint: 12-month Freedom From New Symptomatic Pulmonary Embolism (PE)
Endpoint domain: Mortality/survival
Primary endpoint: 12-month Freedom From Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of Occult Pathologic N2 Lymph Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: successful decolonization of S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vestibulo-ocular Reflex Gain Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality in the first month after diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of RXI-109
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of GERD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Subjective psychological effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean heat transfer at cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean heat transfer at warming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Rate of Response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful TAVI from the patient perspective
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient's survival
Endpoint domain: Mortality/survival
Primary endpoint: changes in MMSE (Mini Mental State Examination)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HS-Omega-3 Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peanut specific IgE and IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scanning artifacts on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to correction of SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitative agreement between measured CT and CT synthesized from MR data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative agreement in the derived linear attenuation coefficients at 511 kilo electro volts (keV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a >= 50% Decline in Prostate-specific Antigen (PSA) Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Homework Completed
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: total antibiotic prescribing weighted by STAR-PU
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total broad spectrum antibiotic prescribing weighted by STAR-PU
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percentage broad spectrum antibiotic prescribing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Immunology remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: One-year Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Proportion of Participants Meeting TNSS or Sneezing Score Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in State Hope Scale score ('agency')
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Beck Hopelessness Scale - 4 item version score ('hope')
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the number of emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in the number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in the length (in days) of hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Avoidance of Invasive Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time from evacuation of the uterus to new conception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of patients completing all guideline-recommended diagnostics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Impact of clinical predictors of disease worsening on patient outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal polyuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immunity level (antibodies) against meningococcus C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ventricular Pressure Volume Loop Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in heart failure related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Nitrogen balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Syncope Recurrence Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participant Deaths in the First 12 Months Post-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Coronary heart disease 10 year risk
Endpoint domain: Mortality/survival
Primary endpoint: Emergency department attendance related to COVID-19
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in self-reported life quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity and specificity of FCH PET/CT for intraprostatic localization of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of healthy participants enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use